Menu
Recruiting NCT07066228

Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects

No phase Interventional Defective Composite Restorations Bone Cysts Bone Defect Bone Nonunion

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: tissue-engineered bone.
Who it may be relevant to
Registry conditions: Defective Composite Restorations, Bone Cysts, Bone Defect, Bone Nonunion. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects of Limbs

Overview

Commercial decalcified bone scaffolds were combined with autologous bone marrow mesenchymal stem cells to form tissue engineered bone in vitro to explore the effect of this tissue engineered bone in the clinical repair of long tubular bone defects in limbs.

Detailed description

Bone defects caused by trauma, tumors, and other factors, particularly weight-bearing long tubular bone defects in the limbs, pose significant harm to patients and severely impact their quality of life, remaining a major clinical challenge. Current repair methods such as autologous bone grafting, vascularized autologous bone grafting, allogeneic bone grafting, induced membrane technique, and bone transport technique face limitations including lengthy treatment cycles, high costs, restricted donor sites and bone harvest quantities, and unpredictable outcomes.

To address these challenges, the National Engineering Research Center for Tissue Engineering has developed an innovative approach through continuous research and innovation. This method utilizes autologous bone marrow mesenchymal stem cells (BMSCs) with minimal invasiveness, strong proliferation capacity, and potent osteogenic potential as seed cells for bone construction. These cells are combined with clinically approved allogeneic decalcified bone materials to create tissue-engineered bone through in vitro induction. This approach offers multiple advantages: absence of immune rejection, unrestricted material sources, sufficient cultured bone volume, and high survival rates, providing a new direction for treating long tubular bone defects in limbs.

This study aims to evaluate the clinical efficacy of tissue-engineered bone constructed with autologous BMSCs for repairing long bone defects in extremities, thereby providing evidence-based support for bone defect treatment.

Interventions

  • Device tissue-engineered bone
    Commercial decalcified bone scaffolds were combined with autologous bone marrow mesenchymal stem cells to form tissue engineered bone in vitro

Primary outcome measures

  • The scores of bone healing [Time frame: About 360 days after surgical treatment of bone defect]
  • The adverse event incidence using tissue-engineered bone [Time frame: About 360 days after surgical treatment of bone defect]
  • Bone union (bone healing) evaluation through modified lane and sandhu radiological scoring system [Time frame: At the end of visits 1, 2, 3 (respectively performed at screening and 7, 90, 360 days after the surgery)]
Secondary outcome measures (2)
  • The scores of time of weight loading after operation [Time frame: About 360 days after surgical treatment of bone defect]
  • The scores of pain [Time frame: About 360 days after surgical treatment of bone defect]

Eligibility criteria

Inclusion criteria

  • Age: 18-55 years old, gender unrestricted;
  • Defective nonunion with bone loss exceeding 30% of the bone cross-section and a length of 2-3 cm;
  • Solitary bone cysts involving more than 50% of the bone cross-section.

Exclusion criteria

  • Combined with local tumors, tuberculosis, infections or other bone-healing affecting lesions;
  • Systemic diseases affecting bone healing such as osteofibrous dysplasia, osteogenesis imperfecta, bone dystrophic diseases, and metabolic bone disorders;
  • Moderate-to-severe osteoporosis (BMD: T-score < -2.5);
  • Severe systemic conditions including systemic malnutrition, systemic infectious diseases, severe cardiopulmonary diseases, coagulation disorders, and major organ failure;
  • Complicated with severe brain trauma;
  • Heavy smoking, drug abuse, alcoholism, or other harmful addictions;
  • Psychiatric disorders or patients with menopausal symptoms;
  • Concurrent participation in other studies or recent completion (within 4 weeks) of other clinical trials;
  • Pregnancy, lactation, or planned pregnancy within one year after initial enrollment;
  • Psychological conditions impairing treatment compliance;
  • Congenital malformations of vital organs or other systems;
  • Nonunion caused by malignant tumor resection;
  • Refusal to accept tissue-engineered bone repair protocol.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • The First Affiliated Hospital of Xinxiang Medical College — Xinxiang

Identifiers

NCT: NCT07066228 · TEBLTBD-2022-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗